Q3 2022

Filed Nov 14, 2022 · 10-Q · 45 days after period end · 0001493152-22-032105

Q3 2022 · 10-Q

Revenue—

Net Income

-$810.36K

N/M vs Q3 2021

EPS Diluted

$0.00

— vs Q3 2021

Operating Income-$525,280N/M

Operating Cash Flowderived-$485,456N/M

Same quarter

Metric	Q3 2022	Q3 2021	Q3 2020	Q3 2019
Revenue	—	—	—	$0.00
Net Income	-$810.36K	-$3.19M	-$693.16K	-$1.13M
EPS Diluted	$0.00	$0.00	$0.00	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Kraig Biocraft Laboratories, Inc. · CIK 1413119 · Engraved from SEC EDGAR